Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid

Acta Ophthalmologica

Volumn 92, Issue 6, 2014, Pages 550-556

  Jõhannesson, Gauti ^a,b   Moya Ortega, Maria D ^a,c   Ásgrímsdõttir, Gudrún Marta ^c   Lund, Sigrún H ^a   Thorsteinsdõttir, Margrét ^a   Loftsson, Thorsteinn ^a   Stefánsson, Einar ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b UMEÅ UNIVERSITY   (Sweden)

^c Oculis Ehf   (Iceland)

Author keywords

cyclodextrin nanoparticles; dexamethasone; dorzolamide; Maxidex; tear fluid; Trusopt

Indexed keywords

DEXAMETHASONE; DEXAMETHASONE NANOPARTICLE GAMMA CYCLODEXTRIN EYE DROPS; DORZOLAMIDE; DORZOLAMIDE NANOPARTICLE GAMMA CYCLODEXTRIN EYE DROPS; EYE DROPS; NANOPARTICLE; UNCLASSIFIED DRUG; CARBONATE DEHYDRATASE INHIBITOR; GAMMA CYCLODEXTRIN DERIVATIVE; GLUCOCORTICOID; SULFONAMIDE; SUSPENSION; THIOPHENE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG INSTILLATION; HUMAN; LACRIMAL FLUID; LACRIMAL FLUID LEVEL; MASS SPECTROMETRY; PAIN; PIPETTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STINGING SENSATION; SUSPENSION; BIOAVAILABILITY; CHEMISTRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLISM; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

BIOLOGICAL AVAILABILITY; CARBONIC ANHYDRASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXAMETHASONE; DOUBLE-BLIND METHOD; FEMALE; GAMMA-CYCLODEXTRINS; GLUCOCORTICOIDS; HUMANS; MALE; NANOPARTICLES; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; SULFONAMIDES; SUSPENSIONS; TANDEM MASS SPECTROMETRY; TEARS; THIOPHENES; TISSUE DISTRIBUTION;

EID: 84906322741     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12334     Document Type: Article

References (29)

1. Alcon Laboratories I (2007): Maxidex 0.1% (dexamethasone ophthalmic suspension). Fort Worth, TX: Alcon Laboratories, INC.
2. Boyer DS, Faber D, Gupta S, et al. (2011): Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 31: 915-923.
3. Brechue WF, &, Maren TH, (1993): pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci 34: 2581-2587.
4. Brewster ME, Noppe M, Peeters J, &, Loftsson T, (2007): Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins. Int J Pharm 342: 250-253.
5. Conroy CW, &, Maren TH, (1995): Effect of pH on the ocular distribution of a topical carbonic anhydrase inhibitor. Exp Eye Res 61: 213-222.
6. Gudmundsdottir BS, Petursdottir D, Asgrimsdottir GM, et al. (2013): g-Cyclodextrin Nanoparticle Eye Drops with Dorzolamide-Effect on Intraocular Pressure in Man. J Ocul Pharmacol Ther [Epub ahead of print].
7. Jansook P, Kurkov SV, &, Loftsson T, (2010a): Cyclodextrins as solubilizers: formation of complex aggregates. J Pharm Sci 99: 719-729.
8. Jansook P, Ritthidej GC, Ueda H, Stefansson E, &, Loftsson T, (2010b): yCD/HPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension. J Pharm Pharma Sci 13: 336-350.
9. Jansook P, Stefansson E, Thorsteinsdottir M, Sigurdsson BB, Kristjansdottir SS, Bas JF, Sigurdsson HH, &, Loftsson T, (2010c): Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm 76: 208-214.
10. Kompella UB, Kadam RS, &, Lee VH, (2010): Recent advances in ophthalmic drug delivery. Ther Deliv 1: 435-456.
11. Kristinsson JK, Fridriksdottir H, Thorisdottir S, Sigurdardottir AM, Stefansson E, &, Loftsson T, (1996): Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest Ophthalmol Vis Sci 37: 1199-1203.
12. Loftsson T, (2012): Drug permeation through biomembranes: cyclodextrins and the unstirred water layer. Pharmazie 67: 363-370.
13. Loftsson T, &, Brewster ME, (2010): Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 62: 1607-1621.
14. Loftsson T, &, Brewster ME, (2011): Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol 63: 1119-1135.
15. Loftsson T, &, Duchene D, (2007): Cyclodextrins and their pharmaceutical applications. Int J Pharm 329: 1-11.
16. Loftsson T, &, Masson M, (2001): Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 225: 15-30.
17. Loftsson T, &, Stefansson E, (2002): Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand 80: 144-150.
18. Loftsson T, &, Stefansson E, (2007): Cyclodextrins in ocular drug delivery: theoretical basis with dexamethasone as a sample drug. J Drug Deliv Sci Tech 17: 3-9.
19. Loftsson T, Masson M, &, Brewster ME, (2004): Self-association of cyclodextrins and cyclodextrin complexes. J Pharm Sci 93: 1091-1099.
20. Loftsson T, Hreinsdottir D, &, Stefansson E, (2007a): Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol 59: 629-635.
21. Loftsson T, Vogensen SB, Brewster ME, &, Konradsdottir F, (2007b): Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci 96: 2532-2546.
22. Loftsson T, Jansook P, &, Stefansson E, (2012): Topical drug delivery to the eye: dorzolamide. Acta Ophthalmol 90: 603-608.
23. Maren TH, Bar-Ilan A, Conroy CW, &, Brechue WF, (1990): Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical route. Exp Eye Res 50: 27-36.
24. McGill SL, &, Smyth HD, (2010): Disruption of the mucus barrier by topically applied exogenous particles. Mol Pharm 7: 2280-2288.
25. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. (2011): The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615-625.
26. Sigurdsson HH, Konraethsdottir F, Loftsson T, &, Stefansson E, (2007): Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand 85: 598-602.
27. Tanito M, Hara K, Takai Y, et al. (2011): Topical dexamethasone- cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci 52: 7944-7948.
28. Wei G, Xu H, Ding PT, Li SM, &, Zheng JM, (2002): Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release 83: 65-74.
29. Xu QG, Boylan NJ, Suk JS, et al. (2013): Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo. J Controlled Release 167: 76-84.